Bergman M, Tundia N, Martin N, Suboticki JL, et al. Correction: Patient-reported outcomes of upadacitinib versus abatacept in
patients with rheumatoid arthritis and an inadequate response to biologic
disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3
trial. Arthritis Res Ther 2022;24:248.
PMID: 36329507